Administrator Verma Statement on FDA’s Biosimilars Action Plan
CMS and FDA are both working to accelerate innovation in the biosimilars market – CMS has taken action to do so by providing biosimilars with separate payment codes and by lowering the amount of cost sharing that low-income beneficiaries pay for biosimilars.
Newsroom Press ReleaseMANAGED CARE PLAN EXPANDS TO INCLUDE MEDICARE BENEFICIARIES IN TWO TEXAS COUNTIES
Newsroom Press Release